Clinical Trials on Short Bowel Syndrome (SBS) in South Africa

Total 67 results

Shire

Completed

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

Short Bowel Syndrome

United States, France, Germany, Canada, Netherlands, Poland, Denmark, Belgium, United Kingdom
Amarnath, Rathna, M.D.

Unknown

Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease

Cholestasis | Short Bowel Syndrome

United States
GlaxoSmithKline

Completed

A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS)

Germany, Australia, France
University of Stellenbosch
Nestlè Nutrition Institute Africa; National Research Foundation (NRF) (RSA)

Completed

Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome

Irritable Bowel Syndrome

South Africa
GlaxoSmithKline

Completed

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS)

United States, Canada
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Ardelyx

Enrolling by invitation

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Ono Pharma USA Inc

Completed

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
GlaxoSmithKline

Completed

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States, Australia
GlaxoSmithKline

Completed

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States, Australia
AstraZeneca
Ironwood Pharmaceuticals, Inc.

Completed

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (D5630C00001)

Irritable Bowel Syndrome With Constipation (IBS-C)

United States, Australia, China, New Zealand, Canada
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea (IBS-D)

United States
Société des Produits Nestlé (SPN)

Completed

A Study to Monitor the Use of an Amino Acid-Based Infant Formula (EAGLE)

Short Bowel Syndrome | Cow's Milk Protein Allergy | Eosinophilic Gastrointestinal Disorders | Malabsorption/Maldigestion | Multiple Food Allergies

United States
Rutgers, The State University of New Jersey
Harokopio University

Completed

A Study of Chios Mastic Water in Irritable Bowel Syndrome (MASTIQUA)

Irritable Bowel Syndrome

Greece
Sheffield Teaching Hospitals NHS Foundation Trust

Recruiting

Traditional Dietary Advice Vs. Mediterranean Diet in IBS

Irritable Bowel Syndrome

United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

A Study Comparing the Effectiveness and Convenience of Dietary Therapy for Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome

United Kingdom
GlaxoSmithKline

Completed

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers

Irritable Bowel Syndrome

Australia
Sheffield Teaching Hospitals NHS Foundation Trust
Hotel Dieu Hospital

Unknown

Differences in Preparation for Small Bowel Capsule Endoscopy

Inflammatory Bowel Diseases | Celiac Disease | Capsule Endoscopy

United Kingdom, Canada
Ardelyx

Completed

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Bausch Health Americas, Inc.

Completed

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 2)

Non-Constipation Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Diarrhea-predominant Irritable Bowel Syndrome

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Menarini Group

Completed

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-3)

Irritable Bowel Syndrome With Diarrhea

France, Italy, Spain, United States, Russian Federation, Germany, Bulgaria, Poland, United Kingdom, Romania, Czech Republic
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
CinPhloro Pharma, LLC

Recruiting

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

Irritable Bowel Syndrome With Diarrhea

United States
Tioga Pharmaceuticals
RTI Health Solutions

Completed

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Diarrhea Predominant Irritable Bowel Syndrome

United States
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
OrphoMed, Inc.
PPD

Completed

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Irritable Bowel Syndrome With Diarrhea

United States
DiaSorin Inc.

Completed

Fecal Calprotectin Collection Protocol (CALFE)

Irritable Bowel Syndrome | Abdominal Pain | Constipation | Inflammatory Bowel Diseases | Weight Loss | Celiac Disease | Crohn Disease | Ulcerative Colitis | Diverticulitis | Food Intolerance | Chronic Diarrhea | Indeterminate Colitis | Distension

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
Urovant Sciences GmbH

Completed

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
AbbVie
Ironwood Pharmaceuticals, Inc.

Enrolling by invitation

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Canada, Israel, Netherlands
Ironwood Pharmaceuticals, Inc.

Completed

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States, Canada
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS)

Irritable Bowel Syndrome Characterized by Constipation

United States
Menarini Group

Terminated

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-4)

Irritable Bowel Syndrome With Diarrhea

Germany, Sweden, United States, United Kingdom, Hungary, Poland, Latvia, Slovakia, Czech Republic
Alizyme

Terminated

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Constipation-Predominant Irritable Bowel Syndrome

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Arena Pharmaceuticals

Terminated

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) (CAPTIVATE)

Irritable Bowel Syndrome

United States
AbbVie
Ironwood Pharmaceuticals, Inc.

Active, not recruiting

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (LINZESS)

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
Capso Vision, Inc.

Completed

Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease

Ulcer | Celiac Disease | Crohn Disease | Inflammatory Bowel Disease | Intestinal Disease

United States, Canada
Bausch Health Americas, Inc.

Completed

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Bausch Health Americas, Inc.

Completed

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study (TARGET3)

Irritable Bowel Syndrome With Diarrhea

United States, United Kingdom, Germany
Procter and Gamble
Alimentary Health Ltd

Completed

Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome

Irritable Bowel Syndrome

United Kingdom

Clinical Trials on Short Bowel Syndrome (SBS) in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations